Alto Neuroscience ANRO Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $264.26M+63.9% | $176.98M+4.9% | $138.32M-24.1% | $148.09M-23.5% | $161.25M-21.7% | ||
| $269.13M+64.6% | $177.72M+4.9% | $139.45M-24.0% | $149.85M-23.3% | $163.52M-21.5% | ||
| $2.23M-9.8% | $1.87M-29.8% | $2.03M-13.8% | $2.31M+60.1% | $2.48M+59.4% | ||
| $276.26M+60.7% | $184.69M+4.0% | $147.01M-23.3% | $157.88M-20.0% | $171.92M-18.1% | ||
| $3.37M+143% | $1.88M+18.9% | $2.06M-8.6% | $1.67M-9.3% | $1.38M-42.6% | ||
| $2.14M— | $585K— | —— | —— | —— | ||
| $13.12M+80.7% | $11.33M+13.2% | $9.05M-35.5% | $8.13M-17.4% | $7.26M-9.4% | ||
| $13.89M-30.4% | $16.17M+57.7% | $20.31M+207% | $20.12M+160% | $19.94M+126% | ||
| $32.89M+0.2% | $33.55M+28.6% | $35.45M+33.5% | $34.47M+96.0% | $32.82M+95.1% | ||
| $3K0.0% | $3K0.0% | $3K0.0% | $3K0.0% | $3K0.0% | ||
| -$227.87M-48.4% | -$201.63M-45.7% | -$185.45M-50.5% | -$171.27M-61.0% | -$153.57M-69.9% | ||
| $243.37M+75.0% | $151.14M-0.2% | $111.56M-32.4% | $123.41M-31.4% | $139.1M-28.0% | ||
| $276.26M+60.7% | $184.69M+4.0% | $147.01M-23.3% | $157.88M-20.0% | $171.92M-18.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Alto Neuroscience's total assets?
- Alto Neuroscience (ANRO) holds $276.3M in total assets, up 60.7% year over year.
- How much debt does Alto Neuroscience have?
- Alto Neuroscience carries $20.9M in total debt against $243.4M of shareholders' equity, a debt-to-equity ratio of 0.09.
- How much cash does Alto Neuroscience have?
- Alto Neuroscience holds $264.3M in cash and equivalents.
- Can Alto Neuroscience cover its short-term obligations?
- Its current ratio is 20.52 — current assets exceed current liabilities.
- Where does Alto Neuroscience's balance sheet data come from?
- Every line is extracted from Alto Neuroscience's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.